Top

Published in:

01-05-2008 | Original Article

Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma

Authors: Anna De Geer, Lena-Maria Carlson, Per Kogner, Jelena Levitskaya

Published in: Cancer Immunology, Immunotherapy | Issue 5/2008

Abstract

Neuroblastoma (NB) is often described as an unfavorable target for both HLA-restricted and death receptor-mediated elimination by cytotoxic T lymphocytes (CTLs) due to low or absent HLA class I and caspase-8 expression. We investigated the effects of soluble factors released by CTLs activated by TCR triggering (named as activated supernatant; AS) on the levels and composition of cell surface molecules involved in HLA-restricted and HLA-independent NB cell recognition (surface immune phenotype). Using a panel of long-term propagated NB cell lines and freshly isolated primary human NB cells, we analyzed surface expression of the (1) cognate receptors for TNFα, Fas and TRAIL; (2) HLA class I and II heterodimers; (3) adhesion molecules; (4) the intracellular expression and activation of caspase-8, as well as (5) the susceptibility of NB cells to death receptor-mediated killing prior to and after exposure to AS. The exposure of NB cells to soluble factors released by activated CTLs skewed the surface immune phenotype of both long term cultured and primary NB cells, induced the expression and activation of caspase-8 and increased the susceptibility of tumor cells to lysis by TRAIL and Fas-agonistic antibody. Blocking experiments identified IFNγ and TNFα as main factors responsible for modulating the surface antigens of NB cells by AS. Our data suggest that recruitment of CTLs activated on third party targets into the vicinity of the NB tumor mass, may override the “silent” immune phenotype of NB cells via the action of soluble factors.

Available only for authorised users

Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420–430PubMedCrossRef

Blaheta RA, Daher FH, Michaelis M, Hasenberg C, Weich EM, Jonas D, Kotchetkov R, Doerr HW, Cinatl J Jr (2006) Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC Cancer 6:294PubMedCrossRef

Blaheta RA, Hundemer M, Mayer G, Vogel JU, Kornhuber B, Cinatl J, Markus BH, Driever PH, Cinatl J Jr (2002) Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of neuroblastoma cells to adhere to endothelium in vitro. Cell Commun Adhes 9:131–147PubMedCrossRef

Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203–216PubMedCrossRef

Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477PubMed

Cerwenka A, Lanier LL (2001) Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 181:158–169PubMedCrossRef

Cook JR, Myers NB, Hansen TH (1996) The mechanisms of peptide exchange and beta 2-microglobulin exchange on cell surface Ld and Kb molecules are noncooperative. J Immunol 157:2256–2261PubMed

Cooper MJ, Hutchins GM, Mennie RJ, Israel MA (1990) Beta 2-microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation. Cancer Res 50:3694–3700PubMed

Corrias MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P, Pistoia V, Ferrini S (2001) Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens 57:110–117PubMedCrossRef

10.

De Geer A, Kiessling R, Levitsky V, Levitskaya J (2006) Cytotoxic T lymphocytes induce caspase-dependent and -independent cell death in neuroblastomas in a MHC-nonrestricted fashion. J Immunol 177:7540–7550PubMed

11.

Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, Brodeur GM (2001) Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61:1314–1319PubMed

12.

Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ikegaki N, Brodeur GM (2000) Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med Pediatr Oncol 35:603–607PubMedCrossRef

13.

ElOjeimy S, McKillop JC, El-Zawahry AM, Holman DH, Liu X, Schwartz DA, Day TA, Dong JY, Norris JS (2006) FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther 13:739–745PubMedCrossRef

14.

Feltner DE, Cooper M, Weber J, Israel MA, Thiele CJ (1989) Expression of class I histocompatibility antigens in neuroectodermal tumors is independent of the expression of a transfected neuroblastoma myc gene. J Immunol 143:4292–4299PubMed

15.

Fulda S, Debatin KM (2002) IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21:2295–2308PubMedCrossRef

16.

Fulda S, Debatin KM (2006) 5-Aza-2′-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene. 25:5125–5133PubMedCrossRef

17.

Hellstrom KE, Hellstrom I (1972) Immunity to neuroblastomas and melanomas. Annu Rev Med 23:19–38PubMedCrossRef

18.

Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N (2000) Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60:4315–4319PubMed

19.

Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N (2000) Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol 35:608–611PubMedCrossRef

20.

Huang Y, Sheikh MS (2006) TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol (in press)

21.

Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954–960PubMedCrossRef

22.

Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190–195PubMedCrossRef

23.

Kalos M (2003) Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 21:781–786PubMedCrossRef

24.

Kim S, Kang J, Evers BM, Chung DH (2004) Interferon-gamma induces caspase-8 in neuroblastomas without affecting methylation of caspase-8 promoter. J Pediatr Surg 39:509–515PubMedCrossRef

25.

Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H (1993) Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 53:2044–2050PubMed

26.

Kummer JA, Micheau O, Schneider P, Bovenschen N, Broekhuizen R, Quadir R, Strik MC, Hack CE, Tschopp J (2007) Ectopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosis. Cell Death Differ 14:1486–1496PubMedCrossRef

27.

Lampson LA, Fisher CA, Whelan JP (1983) Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 130:2471–2478PubMed

28.

Lampson LA, Whelan JP, Fisher CA (1985) HLA-A,B,C and beta 2-microglobulin are expressed weakly by human cells of neuronal origin, but can be induced in neuroblastoma cell lines by interferon. Prog Clin Biol Res 175:379–388PubMed

29.

Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225–274PubMedCrossRef

30.

Le LH, Hirte HW, Hotte SJ, Maclean M, Iacobucci A, Corey A, Fox NL, Oza AM (2004) Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin’s lymphoma (NHL). J Clin Oncol (Meeting Abstracts) 22:2533

31.

Main EK, Monos DS, Lampson LA (1988) IFN-treated neuroblastoma cell lines remain resistant to T cell-mediated allo-killing, and susceptible to non-MHC-restricted cytotoxicity. J Immunol 141:2943–2950PubMed

32.

Marozzi A, Meneveri R, Bunone G, De Santis C, Lopalco L, Beretta A, Agresti A, Siccardi AG, Della Valle G, Ginelli E (1993) Expression of beta 2m-free HLA class I heavy chains in neuroblastoma cell lines. Scand J Immunol 37:661–667PubMedCrossRef

33.

Martin RF, Beckwith JB (1968) Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance. J Pediatr Surg 3:161–164PubMedCrossRef

34.

Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847–854PubMedCrossRef

35.

Parham P, Barnstable CJ, Bodmer WF (1979) Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. J Immunol 123:342–349PubMed

36.

Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171:1918–1926PubMed

37.

Reed JC (2006) Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 3:388–398PubMedCrossRef

38.

Russell JH, Ley TJ (2002) Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20:323–370PubMedCrossRef

39.

Squire R, Fowler CL, Brooks SP, Rich GA, Cooney DR (1990) The relationship of class I MHC antigen expression to stage IV-S disease and survival in neuroblastoma. J Pediatr Surg 25:381–386PubMedCrossRef

40.

Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh DA (2006) Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439:95–99PubMedCrossRef

41.

Sugimoto T, Horii Y, Hino T, Kemshead JT, Kuroda H, Sawada T, Morioka H, Imanishi J, Inoko H (1989) Differential susceptibility of HLA class II antigens induced by gamma-interferon in human neuroblastoma cell lines. Cancer Res 49:1824–1828PubMed

42.

Teitz T, Lahti JM, Kidd VJ (2001) Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med 79:428–436PubMedCrossRef

43.

Teitz T, Stupack DG, Lahti JM (2006) Halting neuroblastoma metastasis by controlling integrin-mediated death. Cell Cycle 5:681–685PubMed

44.

Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6:529–535PubMedCrossRef

45.

Tekautz TM, Zhu K, Grenet J, Kaushal D, Kidd VJ, Lahti JM (2006) Evaluation of IFN-gamma effects on apoptosis and gene expression in neuroblastoma—preclinical studies. Biochim Biophys Acta 1763:1000–1010PubMedCrossRef

46.

Thorburn A (2004) Death receptor-induced cell killing. Cell Signal 16:139–144PubMedCrossRef

47.

Vertuani S, De Geer A, Levitsky V, Kogner P, Kiessling R, Levitskaya J (2003) Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res 63:8006–8013PubMed

48.

Warzynski MJ, Graham DM, Axtell RA, Higgins JV, Hammers YA (2002) Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients. Cytometry 50:298–304PubMedCrossRef

49.

Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F (2005) Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 54:400–406PubMedCrossRef

50.

Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, Mackall CL, Thiele CJ (2003) Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res 63:1122–1129PubMed

51.

Yuan J (1997) Transducing signals of life and death. Curr Opin Cell Biol 9:247–251PubMedCrossRef

Title: Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma
Authors: Anna De Geer
Lena-Maria Carlson
Per Kogner
Jelena Levitskaya
Publication date: 01-05-2008
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 5/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-007-0412-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Migration deficit in monocyte-macrophages in human ovarian cancer

Clinical impact of HLA class I expression in rectal cancer

Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2

Adoptive transfer of Treg depleted autologous T cells in advanced renal cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer